Chief Judge Backs Broader DNA Testing
By AP,
Associated Press
| 02. 15. 2012
ALBANY — New York’s chief judge urged lawmakers Tuesday to require DNA testing for every felony and criminal misdemeanor conviction and to give defendants who plead guilty to serious felonies greater access to genetic evidence from crime scenes.
Currently, the state limits DNA testing to certain felony and misdemeanor convictions and a person who pleads guilty isn’t entitled to DNA testing if the test results are not part of the prosecution evidence.
But in his annual address on the state of the judiciary, Chief Judge Jonathan Lippman said experience has shown wrongful convictions even in cases where a defendant pleaded guilty. He outlined and endorsed legislative proposals meant to address the potential for wrongful convictions, recommendations that came from a task force including defense attorneys, judges, prosecutors, police, academics and others.
“It’s a stain on the justice system,” Lippman said later of any conviction of someone who didn’t commit the crime. “Our recommendations have no agenda politically.”
Gov. Andrew Cuomo is pushing to expand the state DNA databank beyond samples from those convicted of penal felonies and 36 misdemeanors. The...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...